Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome)

Antoine Hommais; Julie Rayes; Anne Houllier; Bernadette Obert; Paulette Legendre; Agnes Veyradier; Jean-Pierre Girma; Anne-Sophie Ribba

doi:10.1160/TH07-01-0059

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 98(03): 593-599
DOI: 10.1160/TH07-01-0059

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome)

Authors

Antoine Hommais

¹INSERM U770 and Université Paris-Sud, Faculté de Médecine IFR93, Le Kremlin-Bicêtre, France
Julie Rayes

¹INSERM U770 and Université Paris-Sud, Faculté de Médecine IFR93, Le Kremlin-Bicêtre, France
Anne Houllier

¹INSERM U770 and Université Paris-Sud, Faculté de Médecine IFR93, Le Kremlin-Bicêtre, France
Bernadette Obert

¹INSERM U770 and Université Paris-Sud, Faculté de Médecine IFR93, Le Kremlin-Bicêtre, France
Paulette Legendre

¹INSERM U770 and Université Paris-Sud, Faculté de Médecine IFR93, Le Kremlin-Bicêtre, France
Agnes Veyradier

¹INSERM U770 and Université Paris-Sud, Faculté de Médecine IFR93, Le Kremlin-Bicêtre, France
Jean-Pierre Girma

¹INSERM U770 and Université Paris-Sud, Faculté de Médecine IFR93, Le Kremlin-Bicêtre, France
Anne-Sophie Ribba

¹INSERM U770 and Université Paris-Sud, Faculté de Médecine IFR93, Le Kremlin-Bicêtre, France

Abstract

Summary

ADAMTS13 mutations S203P, R268P, R507Q and A596V were previously identified in French patients with hereditary thrombotic thrombocytopenic purpura (TTP) (Upshaw-Schulman syndrome). Mutated recombinant (r) ADAMTS13 were transiently expressed in COS-7 cells and characterized in comparison with wild-type (WT) rADAMTS13.ADAMTS13 antigen was qualitatively and quantitatively estimated by electrophoretic analysis and ELISA. Enzymatic activity was qualitatively and quantitatively estimated using GST-VWF73,FRETS-VWF73 fragments and full-length rVWF-WT as substrates. The four mutants and rADAMTS13-WT were present within the cells. Secretion level of rADAMTS13-WT reached 1,200 ng/ml. The four mutations strongly altered the secretion and biological activity of rADAMTS13. The percentage secretion was 21, 38 and 17% for rADAMTS13-S203P, -R268P and -A596V compared with rADAMTS13- WT. rADAMTS13-R507Q concentration was under the detection limit of the assay. In the four cases, no enzymatic activity was detected. After concentration, we confirmed that mutations S203P and R268P totally abolished the proteolytic activity of ADAMTS13. Due to the very low protease concentration, activity of rADAMTS13-R507Q was below the threshold of the assays. rADAMTS13-A596V had no proteolytic activity towards the full-length rVWF-WT whereas it exhibited a decreased specific activity of about 30% of that of rADAMTS13- WT towards FRETS-VWF73 fragment. Binding study of mutated rADAMTS13-S203P, -R268P and -A596V showed that the three mutations strongly decreased the interaction of ADAMTS13 with VWF. In conclusion, the four mutations, which led to a secretion defect, a loss of enzymatic activity and a decreased binding to the substrate, are responsible for the hereditary TTP in patients.

Keywords

ADAMTS13 - mutations - recombinant proteins - thrombotic thrombocytopenic purpura (TTP)

Full Text

References

References
1 Sadler JE. von Willebrand factor: two sides of a coin. J Thromb Haemost 2005; 3: 1702-1709.
2 Dent JA, Berkowitz SD, Ware J. et al. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990; 87: 6306-6310.
3 Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005; 3: 1710-1716.
4 Zimmerman TS, Dent JA, Ruggeri ZM. et al. Subunit composition of plasma von Willebrand Factor. Cleavage is present in normal individuals, increased in type IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest 1986; 77: 947-951.
5 Gerritsen HE, Robles R, Lammle B. et al. Partial amino acid sequence of purified von Willebrand factorcleaving protease. Blood 2001; 98: 1654-1661.
6 Fujikawa K, Suzuki H, McMullen B. et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-1666.
7 Zheng XL, Chung D, Takayama TK. et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-41063.
8 Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234.
9 Zheng X, Nishio K, Majerus EM. et al. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 2003; 278: 30136-30141.
10 Soejima K, Matsumoto M, Kokame K. et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003; 102: 3232-3237.
11 Moake JL. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol 2004; 41: 4-14.
12 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
13 Assink K, Schiphorst R, Allford S. et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003; 63: 1995-1999.
14 Kokame K, Matsumoto M, Soejima K. et al. Mutations and common polymorphisms in ADAMTS13 gene responsiblefor von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002; 99: 11902-11907.
15 Kokame K, Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Semin Hematol 2004; 41: 34-40.
16 Matsumoto M, Kokame K, Soejima K. et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2004; 103: 1305-1310.
17 Pimanda JE, Maekawa A, Wind T. et al. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood 2004; 103: 627-629.
18 Uchida T, Wada H, Mizutani M. et al. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood 2004; 104: 2081-2083.
19 Veyradier A, Lavergne JM, Ribba AS. et al. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2004; 2: 424-429.
20 Lammle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005; 3: 1663-1675.
21 Donadelli R, Banterla F, Galbusera M. et al. Invitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 96: 454-464.
22 Peyvandi F, Lavoretano S, Palla R. et al. Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Hum Mutat 2006; 27: 330-336.
23 Schneppenheim R, Kremer Hovinga JA, Becker T. et al. A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost 2006; 96: 3-6.
24 Tao Z, Anthony K, Peng Y. et al. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4: 1931-1935.
25 Obert B, Houllier A, Meyer D. et al. Conformational changes in the A3 domain of von Willebrand factor modulate the interaction of the A1 domain with platelet glycoprotein Ib. Blood 1999; 93: 1959-1968.
26 Kokame K, Matsumoto M, Fujimura Y. et al. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004; 103: 607-612.
27 Kokame K, Nobe Y, Kokubo Y. et al. FRETSVWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
28 Obert B, Tout H, Veyradier A. et al. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 1999; 82: 1382-1385.
29 Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
30 Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 2005; 280: 21773-21778.
31 Ai J, Smith P, Wang S. et al. The proximal carboxyl terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of Von Willebrand factor. J Biol Chem 2005; 280: 29428-29434.
32 Tao Z, Wang Y, Choi H. et al. Cleavage of ultralarge multimers of Von Willebrand factor by C-terminal truncated mutants of ADAMTS-13 under flow. Blood 2005; 106: 141-143.
33 Tao Z, Peng Y, Nolasco L. et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 2005; 106: 4139-4145.
34 Zhou W, Tsai HM. The carboxyl-terminal domains of ADAMTS13 cause substrate-dependent divergence of ADAMTS13 activity. Blood (ASH Annual Meeting) 2006; 108: 381 (Abstract).
35 Nishio K, Anderson PJ, Zheng XL. et al. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci USA 2004; 101: 10578-10583.